Table 2 Key clinical outcomes of Menin inhibitors in ASH 2023
From: Menin inhibitors for acute myeloid leukemia: latest updates from the 2023 ASH Annual Meeting
Inhibitor | Study Name | Patient Population | Key Efficacy Outcomes | Safety Profile |
|---|---|---|---|---|
Revumenib | AUGMENT-101 | Relapsed/refractory KMT2Ar AML | CR + CRh: 22.8% (21/94), CRc: 43.9% (41/94), ORR: 63.2% (59/94) | Manageable; differentiation syndrome (16.0%), febrile neutropenia (13.8%), and QTc prolongation (13.8%); |
Revumenib | Post-HSCT Study | Post-HSCT patients | CR: 6/9, MRD negativity: 5/9 | Manageable; no new safety signals, common AEs included cytopenias (20%) and infections (10%) |
Ziftomenib | Komet-008 | Relapsed/refractory AML | Not available | Manageable; common AEs included anemia (25%), pneumonia (20%), thrombocytopenia (15%), neutropenia (15%) |
DSP-5336 | N/A | MLLr and NPM1 mutated AML | CR with incomplete recovery: 1/6, morphologic leukemia-free state: 1/6 | Not available |
BMF-219 | COVALENT-101 | Relapsed/refractory acute leukemia | CR: 2/5 | Vomiting 13% (3) and Differentiation Syndrome (DS) 13% (3). No Grade 5 TRAEs were reported. |
JNJ-75,276,617 | Phase 1 Study | Relapsed/refractory AML | CR + CRh: 22.8% (21/94), CRc: 43.9% (41/94), ORR: 63.2% (59/94) | Differentiation syndrome (8 [14%]), neutropenia (6 [10%]), anemia and thrombocytopenia (4 [7%] each). |